Hexo: Analysts Anticipate $34.4 Million In Q3 Revenues

Hexo Corp (TSX: HEXO) (NYSE: HEXO) announced that they will be reporting their fiscal third quarter financials before the market opens on June 14th.

Analysts have a consensus C$9.47 12-month price target on the company, via a total of 25 analysts, with three analysts having buy ratings, eight analysts have hold ratings and a single analyst has a strong sell rating. The street high comes from Alliance Global with a C$14 price target, and the lowest target comes from Bryan Garnier with a C$4 price target.

10 analysts have revenue estimates for the third quarter. The mean between all 10 is C$34.42 million; this number has been steady since the start of the year. The street high is C$36.90 million while the lowest sits at C$28.30 million.

Six analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 36.08%, with this number being flat since the start of the year. Street high goes to Stifel-GMP with a 37% estimate and the lowest sits at 35.1%.

Onto EBITDA estimates, there are currently 10 analysts who have third quarter EBITDA estimates. The mean is currently C$0.068 million, with this number being lower at the start of the year. Street high goes to Oppenheimer with a C$2.6 million EBITDA estimate and the lowest being a (C$2) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Three Million Ounces of Gold, Barely Getting Started | Dylan Langille – White Gold

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Dollarama: Canaccord Maintains $57 Price Target

On September 9, Dollarama Inc (TSX: DOL) reported their fiscal second quarter results for the...

Monday, September 13, 2021, 10:52:00 AM

Hexo Corp Share Consolidation To Go Into Effect December 23

Hexo Corp (TSX: HEXO) (NYSE: HEXO) announced this evening after the close of markets that...

Friday, December 18, 2020, 06:25:35 PM

Hexo Corp Targets Black Market with $4.49 Per Gram Product

Hexo Corp (TSX: HEXO) (NYSE: HEXO) announced this morning their plan to target the black...

Wednesday, October 16, 2019, 09:24:49 AM

PLBY Group: Canaccord Nearly Doubles Price Target

PLBY Group (NASDAQ: PLBY) reported their first quarter financial results earlier this week. The company...

Friday, May 14, 2021, 06:12:00 PM

CIBC: Cronos Group CEO Switch Up Is “Somewhat Surprising”

This past week, Cronos Group (TSX: CRON) (NASDAQ: CRON) announced that its Board of Directors...

Saturday, September 12, 2020, 01:45:00 PM